Need professional-grade analysis? Visit stockanalysis.com
$516.87M
N/A
N/A
N/A
Immix Biopharma Inc (IMMX) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $10.35, up 3.92% from the previous close.
Over the past year, IMMX has traded between a low of $1.71 and a high of $10.46. The stock has gained 505.3% over this period. It is currently 505.3% above its 52-week low.
Immix Biopharma Inc has a market capitalization of $516.87M.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Side-by-side comparison against top Healthcare peers.